RPTX News and Press, Repare Therapeutics Inc. From 02/03/22

RPTX - Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that membe...

RPTX - Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate...

RPTX - Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

Former CCO of Y-mAbs Therapeutics brings 20 years of pharma and biotech commercial leadership Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment...

RPTX - Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd...

RPTX - Dosing underway in Repare Therapeutics' Phase 1 trial of RP-6306 in solid tumors

Repare Therapeutics (RPTX -0.3%) announces the first patient has been dosed in its Phase 1 clinical trial of RP-6306, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors (the MAGNETIC trial). MAGNETIC will assess the safety and tolerability of ...

RPTX - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discover and develop novel therapeutics, today announced the first patient has ...

RPTX - Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each ...

RPTX - Repare Therapeutics EPS misses by $0.14, misses on revenue

Repare Therapeutics (NASDAQ:RPTX): Q3 GAAP EPS of -$0.83 misses by $0.14. Revenue of $0.28M misses by $0.75M. Press Release Cash and cash equivalents, restricted cash and marketable securities as of September 30, 2021 were $268.2 million, exclusive of the proceeds from the follow-on public of...

RPTX - Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations...

RPTX - Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,...

Company Name:	Repare Therapeutics Inc.
Stock Symbol:	RPTX
Market:	NASDAQ
Website:	reparerx.com